Aurora Cannabis

ACB

Market cap $256M

The big question for marijuana stock investors is how the market will react to the newly passed bill to reverse the 2018 Farm Bill. A new bill was recently passed with language that essentially overturned the Hemp laws in the USA. Many legal operators produced hemp and CBD products to ensure compliance under the bill as a way to energetically take part in the industry. Now, legal operators in legal states cultivating cannabis vs hemp have an entirely different legal road map to follow. Yet this is what many are calling a step backwards, and rightfully so.

Aurora Cannabis reported Q2/FY2026 results largely in line with expectations previously outlined by management. High margin medical cannabis revenue increased by 15% year-over-year and 9% quarter-over-quarter driven by strong sales in Germany and Poland. On the flip side, sales in Australia declined for a second consecutive quarter due to increasing competition. The disappointing performance resulted in the requirement to take a sizeable impairment charge.

Aurora Cannabis Inc. ( ACB:CA ) Q2 2026 Earnings Call November 5, 2025 8:00 AM EST Company Participants Simona King - Chief Financial Officer Miguel Martin - CEO & Executive Chairman Conference Call Participants William Kirk - ROTH Capital Partners, LLC, Research Division Frederico Yokota Gomes - ATB Capital Markets Inc., Research Division Derek Lessard - TD Cowen, Research Division Pablo Zuanic - Zuanic & Associates Presentation Operator Greetings, and welcome to Aurora Cannabis Inc. Fiscal Second Quarter 2026 Results Conference Call. [Operator Instructions] The conference is being recorded today, Wednesday, November 5, 2025.

Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB) on Wednesday reported second quarter fiscal 2026 net revenue that rose 11% year over year to C$90.4 million, boosted by a 15% increase in medical cannabis sales.  Analysts, on average, were expecting revenue of C$87.33 million.

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago.

Expands YoY Global Medical Cannabis Net Revenue 1 by 15% to Record $70.5 million Increases International Medical Cannabis Net Revenue 1 by 22% to Record $42.7 million, with leadership positions across key markets Delivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2 NASDAQ | TSX: ACB EDMONTON, AB , Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025. "Aurora's quarterly performance highlights our continued focus on profitable growth.

The Canadian cannabis market continues to evolve as global demand expands and U.S. legalization remains a hot topic. Investors are watching closely as several major producers position themselves for renewed growth through product diversification and strategic international expansion. Despite a challenging regulatory and pricing environment, many companies are shifting focus toward profitability, cost reduction, and high-margin opportunities such as medical exports and branded products.

Cannabis stocks could rally on hopes for new hemp regulations and Trump's possible softer stance on marijuana, fueling investor optimism across the industry.

The cannabis industry continues to evolve as investors prepare for potential U.S. federal reform and international market expansion. Despite short-term volatility, global demand for both medical and recreational cannabis is increasing. Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes. However, navigating this emerging sector requires careful attention to fundamentals, technical analysis, and disciplined risk management. Traders should focus on companies that show financial stability, market expansion, and consistent revenue growth before the next wave of legalization news.

NASDAQ | TSX: ACB EDMONTON, AB , Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m.